Growth hormone peptides compared

Ipamorelin vs tesamorelin

A growth hormone secretagogue and a growth hormone-releasing factor analog, with each figure tied to its own label or study.

A 1998 study describes ipamorelin as a pentapeptide and the first GHRP-receptor agonist with a selectivity for GH release similar to that of GHRH, and the Egrifta WR label describes tesamorelin as a synthetic analog of human growth hormone-releasing factor.1,2 In healthy men given 15-minute infusions, ipamorelin had a terminal half-life of 2 hours, and the Egrifta WR label gives tesamorelin a mean elimination half-life of 11 minutes in healthy subjects.3,2

Tesamorelin is labelled in the US as Egrifta WR for excess abdominal fat in HIV-infected adults with lipodystrophy, and FDA placed ipamorelin acetate in 503B category 2, its list of compounding substances that may present significant safety risks, on September 29, 2023.2,4 No label for ipamorelin was found.

FactIpamorelinTesamorelin
What it isA pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, with a selectivity for GH release similar to that of GHRH1A synthetic analog of human growth hormone-releasing factor: its 44 amino acid sequence with a hexenoyl moiety2
How it comesNo label was found; given as 15-minute infusions in a pharmacokinetic study and as twice-daily intravenous infusions in a surgery trial3,7An 11.6 mg vial, for subcutaneous injection2
Half-lifeA terminal half-life of 2 hours after 15-minute infusions in healthy men3
  • 11 minutes in healthy subjects after a single 1.28 mg subcutaneous dose, on the Egrifta WR label2
  • 26 minutes in healthy subjects and 38 minutes in HIV-infected patients after 14 days of daily subcutaneous dosing, on the original Egrifta label8
Studied doses
  • Healthy men: 4.21 to 140.45 nmol/kg infused over 15 minutes, eight men at each of 5 dose levels3
  • Surgery trial: 0.03 mg/kg or placebo by intravenous infusion twice daily, from postoperative day 1 to 7 or discharge7
  • US label: 1.28 mg subcutaneously once daily2
  • Trial on the label: 2 mg or placebo subcutaneously daily for 26 weeks2
StatusFDA placed ipamorelin acetate on its 503B list of substances that may present significant safety risks on September 29, 2023, naming a risk of immunogenicity for certain routes4. WADA names ipamorelin among growth hormone secretagogues, prohibited at all times9US label: excess abdominal fat in HIV-infected adults with lipodystrophy2. WADA names tesamorelin among GHRH analogues, prohibited at all times9

Get the app

Contents6
  1. 1How they differ
  2. 2Levels after one dose
  3. 3Logged in Milligram
  4. 4What is not known
  5. 5References
  6. 6Related pages

Last reviewed . Sources are listed below.

How they differ

The Egrifta WR label states that tesamorelin binds and stimulates human GRF receptors in vitro with similar potency to endogenous GRF, and a 1998 study states that ipamorelin stimulates GH release via a GHRP-like receptor.2,1 In swine in that study, ipamorelin did not release ACTH or cortisol at levels significantly different from GHRH stimulation, even at doses more than 200-fold higher than the ED50 for GH release.1

Levels after one dose

Ipamorelin and tesamorelin after one dose, each as a share of that dose. Each curve follows the half-life its compound page draws, from the Milligram app's model; the sourced half-lives are in the facts table.

Logged in Milligram

  • Ipamorelin: 4% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.
  • Tesamorelin: 11% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.

Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.

What is not known

The Egrifta WR label states that the effects of prolonged elevations in IGF-1 levels are unknown and that long-term cardiovascular safety has not been established.2 A 2026 review notes no long term safety data for ipamorelin, and FDA states that a published study identified serious adverse events, including death, when ipamorelin was given intravenously, and that it lacks sufficient information on certain other injectable routes.5,4 The Egrifta WR label gives an absolute bioavailability of less than 4% after a 2 mg subcutaneous dose; for ipamorelin, no figure measured in people after injection was found, and a study in rats estimated its bioavailability after intranasal application at about 20%.2,6 No study was found that gave both peptides in the same trial.

References

  1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Journal article (rat and swine study), 1998. PMID 9849822
  2. Theratechnologies Inc. EGRIFTA WR (tesamorelin) for injection, prescribing information. Regulatory label, 2026. DailyMed label
  3. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Journal article (clinical trial), 1999. PMID 10496658
  4. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Regulator web page, 2026. fda.gov
  5. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Review article, 2026. PMC13322892
  6. Johansen PB, Hansen KT, Andersen JV, Johansen NL. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Journal article (rat study), 1998. PMID 9879640
  7. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Journal article (phase 2 trial), 2014. PMID 25331030
  8. US Food and Drug Administration. EGRIFTA (tesamorelin for injection) prescribing information, NDA 022505, revised 11/2010. Regulatory label, 2010. accessdata.fda.gov
  9. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. Regulator document, 2026. wada-ama.org